Please enter verification code
Special Issues
Preventive Effects of A Mixture of Micronutrients with Antioxida-tive Properties on Experimentally Induced Prostate Hyperplasia
American Journal of Life Sciences
Volume 1, Issue 1, February 2013, Pages: 22-26
Published: Feb. 20, 2013
Views 3853      Downloads 219
Torricelli P., Department SPES, University of Molise, Campobasso, Italy
Ferorelli P., University of Rome, Tor Vergata, Dept Biology, Roma, Italy
De Martino A., University of Rome, Tor Vergata, Dept Biology, Roma, Italy
Antonelli F., University of Rome, Tor Vergata, Dept Biology, Roma, Italy
Beninati S., University of Rome, Tor Vergata, Dept Biology, Roma, Italy
Article Tools
Follow on us
A mixture of antioxidants found in a commercial food supplement called Citozym (CIZ), showed a preventive capability on experimental prostate hyperplasia induced by testosterone propionate (TP) in C57BL6/N mice. Treatments by CIZ were given orally and started 10 days before the induction of prostate hyperplasia. TP significantly increased prostate size and weight ratio, and this induced increase was significantly inhibited in CIZ-treated mice in comparison with positive controls in a dose-dependent manner. We conclude that CIZ can prevent TP-induced prostate hyperplasia and therefore may be beneficial in the management of benign prostatic hyperplasia.
Antioxidants, Micronutrients, Benign Prostatic Hyperplasia
To cite this article
Torricelli P., Ferorelli P., De Martino A., Antonelli F., Beninati S., Preventive Effects of A Mixture of Micronutrients with Antioxida-tive Properties on Experimentally Induced Prostate Hyperplasia, American Journal of Life Sciences. Vol. 1, No. 1, 2013, pp. 22-26. doi: 10.11648/j.ajls.20130101.14
Ziada A, Rosenblum M & Crawford ED. Benign prostatic hyperplasia: an overview. Urology 1999;53:1–6.
Barnes J. Benign prostatic hyperplasia. Pharm J. 2002;269: 250–252.
Rohrmann S, Giovannucci E, Willett WC & Platz EA. Fruit and vegetable consumption, intake of micronutrients, and benign prostatic hyperplasia in US men. Am J Clin Nutr. 2007;85:523–529.
Willis MS & Wians FH. The role of nutrition in preventing prostate cancer: a review of the proposed mechanism of ac-tion of various dietary substances. Clin Chim Acta 2003;330:57–83.
Manac C, Scalbert A, Morand C, Remezy C & Jimenez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr. 2004;79:727–747.
Middleton E, Kandaswami C & Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev. 2000;52:673–751.
Liao S & Hiipakka RA. Selective inhibition of steroid 5 al-pha-reductase isozymes by tea epicatechin-3-gallate and ep-igallocatechin-3-gallate. Biochem Biophys Res Commun. 1995;214: 833–838.
Antonelli F & Beninati S. Enhanced survival of B16-F10 melanoma tumour-bearing C57BL6/N mice treated with a mixture of antioxidants in: Recent Res Devel in Life Sci. 2011;5:51-60 Research Signpost, Trivandrum India.
Nilsson O, Peter A, Andersson I, Nilsson K, Grundstrom B & Karlsson B. Antigenic determinants of prostate ‐specific antigen (PSA) and development of assays specific for dif-ferent forms of PSA. Br J Cancer 1997;75:789–797.
Bhargava, S, Canda, AE & Chapple, CR. A rational approach to benign prostatic hyperplasia evaluation: recent advances. Curr. Opin. Urol. 2004;14: 1–6.
Aryal M, Pandeya A, Gautam N, Baral N, Lamsal M, Majhi S, Chandra L, Pandit R & Das BK. Oxidative stress in be-nign prostate hyperplasia. Nepal Med Coll J. 2007;9(4):222-224.
Noa M, Arruzazabala ML, Carbajal D, Más R & Molina V.Effect of D-004, a lipid extract from Cuban royal palm fruit, on histological changes of prostate hyperplasia induced with testosterone in rats. Int J Tissue React. 2005;27(4):203-211.
Araki H, Watanabe H, Mishina T & Nakao M. High-risk group for benign prostatic hypertrophy. Prostate, 1983;4:253–264.
Lagiou P, Wuu J, Trichopoulou A, Hsieh CC, Adami HO & Trichopoulos D. Diet and benign prostatic hyperplasia : a study in Greece. Urology, 1999;54: 284–290.
Aryal M, Pandeya A, Gautam N, Baral N, Lamsal M, Majhi S, Chandra L, Pandit R & Das BK. Oxidative stress in be-nign prostate hyperplasia. Nepal Med Coll J. 2007;9:222–224.
Wu F, Tyml K & Wilson JX. Ascorbate inhibits iNOS ex-pression in endotoxin- and IFN gamma-stimulated rat skeletal muscle endothelial cells. FEBS Lett. 2002;520:122–126.
Cindrova-Davies T, Spasic-Boskovic O, Jauniaux E, Char-nock-Jones DS & Burton GJ. Nuclear factor-kappa B, p38, and stress-activated protein kinase mitogen-activated protein kinase signaling pathways regulate proinflammatory cytokines and apoptosis in human placental explants in re-sponse to oxidative stress: effects of antioxidant vitamins. Am J Pathol, 2007;170:1511–1520.
Bowie AG & O'Neill LA. Vitamin C inhibits NF-kappa B activation by TNF via the activation of p38 mitogen-activated protein kinase . J Immunol. 2000;165:7180–7188.
Gao P, Zhang H, Dinavahi R, Li F, Xiang Y, Raman V, Bhujwalla ZM, Felsher DW, Cheng L, Pevsner J, Lee LA, Semenza GL & Dang CV. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 2007;12:230–238.
Nytko KJ, Spielmann P, Camenisch G, Wenger RH & Stiehl DP. Regulated function of the prolyl-4-hydroxylase domain (PHD) oxygen sensor proteins. Antioxid Redox Signal 2007;9:1329–1338.
Vissers MC, Gunningham SP, Morrison MJ, Dachs GU & Currie MJ. Modulation of hypoxia-inducible factor-1 alpha in cultured primary cells by intracellular ascorbate. Free Radic Biol Med. 2007;42:765–772.
Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB & Holick MF. The role of vitamin D in cancer prevention. Am J Public Health, 2006;96: 252–261.
Chen TC & Holick MF. Vitamin D and prostate cancer pre-vention and treatment. Trends Endocrinol Metab. 2003;14:423–430.
G.G. Schwartz GG & Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res. 1990;10:1307–1311.
M.H. Ahonen MH, L. Tenkanen L, L. Teppo L, M. Hakama M, P & Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000;11: 847–852.
Tretli S, Hernes E, Berg JP, Hestvik UE, & Robsahm TE. Association between serum 25(OH)D and death from pros-tate cancer. Br J Cancer. 2009:100:450–454.
Undurti N. Das. Pyruvate is an endogenous anti-infl amatory and anti-oxidant molecule Med Sci Monit, 2006; 12(5): RA79-84.
Faria A, Pestana D, Teixeira D, de Freitas V, Mateus N & Calhau C. Blueberry anthocyanins and pyruvic acid adducts: anticancer properties in breast cancer cell lines. Phytother Res. 2010;24(12):1862-1869.
Pabon M & Lonnerdal B. Effect of citrate on zinc bioavai-lability from milk, milk fractions and infant formulas. Nutr Res. 1992;13:103–111.
Costello LC & Franklin RB. Novel role of zinc in the regu-lation of prostate citrate metabolism and its implications in prostate cancer. Prostate 1998; 35:285−296.
Costello LC, Franklin RB & Narayan P. Citrate in the diag-nosis of prostate cancer. Prostate 1999; 38-237–245.
Lebioda L & Jakob CG. Treating prostate cancer with tartrate ions USA patent n. 5,763,490, 1998.
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
Tel: (001)347-983-5186